Sézary
syndrome, a type of cutaneous T-cell lymphoma, affects Sézary cells
present in the skin, lymph nodes and blood. It accounts approximately 3 to 5
percent of cases of cutaneous T-cell lymphoma. Sézary syndrome is more
prevalent in males compared to females.
It is characterized by red, severely itchy rash that covers
large areas of the body. The common symptoms of Sézary syndrome includes
alopecia, lymphadenopathy, palmoplantar keratoderma, ectropion and
abnormalities of the fingernails and toenails.
Request to Get the Sample Pages at:
The standard treatments for Sézary syndrome are combination
of phototherapy and chemotherapy, and medications including vorinostat and
romidepsin. Takeda Pharmaceutical Company Limited is in the process of
developing brentuximab vedotin for the treatment of Sézary syndrome.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.
